NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.07. The biotechnology company earned $5.68 million during the quarter, compared to analysts' expectations of $5.06 million. Strongbridge Biopharma had a return on equity of 45.77% and a net margin of 211.37%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

5 Wall Street analysts have issued 12 month price targets for Strongbridge Biopharma's shares. Their forecasts range from $8.00 to $18.00. On average, they expect Strongbridge Biopharma's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 302.7% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Media headlines about SBBP stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a decline in short interest in January. As of January 31st, there was short interest totalling 393,800 shares, a decline of 24.1% from the January 15th total of 518,500 shares. Based on an average trading volume of 496,800 shares, the short-interest ratio is presently 0.8 days. Currently, 1.2% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Retrophin (RTRX), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Vanda Pharmaceuticals (VNDA), TherapeuticsMD (TXMD), BioXcel Therapeutics (BTAI), Emisphere Technologies (EMIS), Aprea Therapeutics (APRE), RAPT Therapeutics (RAPT), Omeros (OMER), Vectura Group (VEGPF), Basilea Pharmaceutica (BPMUF), Flexion Therapeutics (FLXN), XBiotech (XBIT) and Phoenix Tree (IMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Genocea Biosciences (GNCA), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE) and Ovid Therapeutics (OVID).

Strongbridge Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.25%), Point72 Asset Management L.P. (1.20%), Renaissance Technologies LLC (1.18%), Diversified Trust Co (0.37%), Alambic Investment Management L.P. (0.22%) and Private Advisors LLC (0.14%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Tredje AP fonden. View Insider Buying and Selling for Strongbridge Biopharma.

SBBP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Diversified Trust Co, Point72 Asset Management L.P., Alambic Investment Management L.P., Bank of Montreal Can, State Street Corp, Acadian Asset Management LLC and Panagora Asset Management Inc.. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $3.29.

Strongbridge Biopharma has a market capitalization of $178.35 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]